Mankind Pharma Ltd. - Research Center
543904 MANKIND Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 9,264.81 | 8,127.15 | 7,486.22 | 5,529.60 | 4,794.41 |
| Operating profit | 2,325.10 | 1,697.38 | 1,838.07 | 1,378.29 | 1,243.46 |
| Interest | 14.57 | 27.75 | 47.12 | 7.98 | 10.62 |
| Gross profit | 2,577.17 | 1,832.42 | 1,994.76 | 1,518.39 | 1,326.69 |
| EPS (Rs) | 45.52 | 31.16 | 34.68 | 27.07 | 23.92 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 266.64 | 162.78 | 203.81 | 148.08 | 93.85 |
| Stock adjustment | -25.36 | 267.89 | -365.27 | -254.25 | -44.51 |
| Raw material | 861.74 | 711.05 | 772.59 | 494.53 | 434.87 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,982.10 | 1,701.38 | 1,462.76 | 1,106.14 | 991.47 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 4,121.22 | 3,749.46 | 3,778.07 | 2,804.89 | 2,169.12 |
| Provisions made | - | - | - | - | - |
| Depreciation | 317.61 | 269.58 | 123.33 | 78.19 | 61.77 |
| Taxation | 436.16 | 314.58 | 482.01 | 355.83 | 306.70 |
| Net profit / loss | 1,823.41 | 1,248.26 | 1,389.42 | 1,084.37 | 958.23 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 40.06 | 40.06 | 40.06 | 40.06 | 40.06 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 25.10 | 20.89 | 24.55 | 24.93 | 25.94 |
| GPM (%) | 27.04 | 22.10 | 25.94 | 26.74 | 27.14 |
| NPM (%) | 19.13 | 15.06 | 18.07 | 19.10 | 19.60 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis